Cefixime Trihydrate (CEF) a broad spectrum oral cephalosporin that was approved by USFDA in 1997 for the treatment of mild to moderate bacterial infections is marketed in combination with Dicloxacillin Sodium (DICLOXA), a narrow spectrum beta-lactam antibiotic of the penicillin class. CEF and DICLOXA were estimated at 254nm by densitometry using silica gel 60/UV254 as stationary phase and a premix of toluene: methanol: triethylamine (5:4:1 v/v) as mobile phase. The method was found linear in a range of 200-600 ng/band for CEF and 500-1500 ng/band for DICLOXA with a correlation coefficient 0.998 for both. CEF and DICLOXA were well resolved with Rf 0.26±0.02 and 0.57±0.02, respectively. The developed high performance thin layer chromatography method was found to be specific, precise and reproducible and can be used for the routine estimation of CEF and DICLOXA in the combined dosage form, available in market.
Loading....